keyword
MENU ▼
Read by QxMD icon Read
search

Recurrent ovarian

keyword
https://www.readbyqxmd.com/read/29043410/determination-of-the-absolute-oral-bioavailability-of-niraparib-by-simultaneous-administration-of-a-14-c-microtracer-and-therapeutic-dose-in-cancer-patients
#1
L van Andel, H Rosing, Z Zhang, L Hughes, V Kansra, M Sanghvi, M M Tibben, A Gebretensae, J H M Schellens, J H Beijnen
INTRODUCTION: Niraparib (Zejula™) is a poly(ADP-ribose) polymerase inhibitor recently approved by the US Food and Drug Administration for the maintenance treatment of patients with recurrent platinum-sensitive epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. The pivotal phase III clinical trial has shown improved progression-free survival in patients receiving niraparib compared with those receiving placebo...
October 17, 2017: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/29042974/curative-effect-of-laparoscopic-hysterectomy-for-uterine-fibroids-and-its-impact-on-ovarian-blood-supply
#2
Xing Wang, Li Lv, Zhiyong Cheng, Xuewu Zhou
This study evaluates the curative effects laparo-scopic hysterectomies performed to treat uterine fibroids and determined the impact of the procedures on ovarian blood supply. A total of 124 patients with uterine fibroids admitted and treated in our hospital from December 2014 to December 2015 participated in the study. Two groups of 62 patients each were formed according to different operating plans; one group of patients underwent abdominal (open) panhysterectomy and were set as the control group; with the other group of patients were treated with laparoscopic hysterectomy and were set as the observation group...
October 2017: Experimental and Therapeutic Medicine
https://www.readbyqxmd.com/read/29042795/significant-association-of-the-exo1-rs851797-polymorphism-with-clinical-outcome-of-ovarian-cancer
#3
Tingyan Shi, Rong Jiang, Pan Wang, Yuan Xu, Sheng Yin, Xi Cheng, Rongyu Zang
BACKGROUND: Exonuclease 1 (EXO1), one of DNA mismatch repair pathway genes, functions in maintaining genomic stability and affects tumor progression. We hypothesized that genetic variations in EXO1 may predict clinical outcomes in epithelial ovarian cancer (EOC). METHODS: In this cohort study with 1,030 consecutive EOC patients, we genotyped four potentially functional polymorphisms in EXO1 by the Taqman assay and evaluated their associations with patients' survival...
2017: OncoTargets and Therapy
https://www.readbyqxmd.com/read/29040187/palliative-radiation-therapy-for-recurrent-ovarian-cancer-efficacy-and-predictors-of-clinical-response
#4
Ginger Jiang, Tracy Balboni, Allison Taylor, Joyce Liu, Larissa J Lee
OBJECTIVE: This study aimed to report response rates and predictors of response to palliative radiotherapy (RT) for recurrent ovarian cancer. METHODS/MATERIALS: Database review identified 64 patients with symptomatic ovarian cancer recurrence who received a total of 76 courses of RT for 103 indications from March 2003 to August 2014. Radiotherapy indications were pain (44%), bleeding (32%), obstruction (15%), and other (9%). Responses were categorized as complete, partial, or none; all response (AR) was the sum of complete and partial responses...
October 17, 2017: International Journal of Gynecological Cancer
https://www.readbyqxmd.com/read/29039536/adipose%C3%A2-derived-mesenchymal-stem-cells-attenuate-cisplatin%C3%A2-induced-apoptosis-in-epithelial-ovarian-cancer-cells
#5
Yiping Wen, Yan Guo, Zaiju Huang, Jing Cai, Zehua Wang
Environment-mediated drug resistance (EMDR) serves an important role in tumor chemotherapy resistance. Adipose‑derived mesenchymal stem cells (ADSC) are an important component of the tumor microenvironment. However, the role of ADSC in EMDR remains unclear. Therefore, in order to clarify whether ADSCs contribute to the cisplatin‑mediated apoptosis in epithelial ovarian cancer (EOC), the present study isolated ADSCs from the omentum of women with benign disease and collected the ADSC culture medium as conditioned medium...
October 12, 2017: Molecular Medicine Reports
https://www.readbyqxmd.com/read/29037806/parp-inhibitors-clinical-utility-and-possibilities-of-overcoming-resistance
#6
REVIEW
Benjamin G Bitler, Zachary L Watson, Lindsay J Wheeler, Kian Behbakht
PARP inhibitors represent a major breakthrough in ovarian cancer care. Almost half of all ovarian cancers have deficiencies in the homologous recombination (HR) DNA repair pathway, namely BRCA1/2 mutations. Given the limited therapeutic options for recurrent ovarian cancer patients there has been a significant effort to develop novel therapies to exploit DNA repair deficiencies. In 2005 and 2006, inhibiting PARP enzymes was first observed to be highly effective against cancers with HR deficiencies. PARP inhibitors are being utilized in the clinic to manage recurrent ovarian cancers that display defects in the HR repair pathway...
October 13, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/29037805/tolerance-and-toxicity-of-the-parp-inhibitor-olaparib-in-older-women-with-epithelial-ovarian-cancer
#7
Lauren E Dockery, William P Tew, Kai Ding, Kathleen N Moore
OBJECTIVES: The objective of this study was to determine the overall tolerability and toxicity of olaparib capsules among older (≥65years) patients with recurrent ovarian cancer treated on 8 completed prospective trials of olaparib. METHODS: An ancillary data analysis of 398 patients with recurrent ovarian cancer enrolled on eight prospective trials of olaparib capsules was performed. Patients aged 65years and older were stratified into age groups by 5year increments (ages 65-69, 70-74, ≥75years) and compared to those <65...
October 13, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/29034309/metastatic-uterine-tumor-resembling-ovarian-sex-cord-tumor-a-case-report-and-review-of-the-literature
#8
Michelle L Kuznicki, Sharon E Robertson, Ardeshir Hakam, Mian M Shahzad
Uterine tumors resembling ovarian sex cord tumors (UTROSCTs) are rare and commonly characterized as benign tumors, with infrequent reports of metastasis and recurrence. Treatment recommendations have not been well established, particularly for more advanced cases. We present the first reported death from a metastatic UTROSCT, summarize the available literature, and describe characteristics common to UTROSCTs with aggressive features. In this case, a 49-year-old woman presented with abdominal distension and pain; initial imaging and diagnostic workup suggested metastatic epithelial ovarian cancer to be the cause...
November 2017: Gynecologic Oncology Reports
https://www.readbyqxmd.com/read/29034306/prolonged-survival-after-intraperitoneal-interleukin-2-immunotherapy-for-recurrent-ovarian-cancer
#9
David R Minor, Samantha P Moores, John K Chan
•A case report of a 14 year remission of recurrent ovarian cancer with intraperitoneal aldesleukin (IL-2) is presented.•Intraperitoneal IL-2 was given with little toxicity.•Immunotherapy may have the potential for durable remissions in ovarian cancer.
November 2017: Gynecologic Oncology Reports
https://www.readbyqxmd.com/read/29033584/dna-ploidy-and-s-phase-fraction-analysis-in-peritoneal-carcinomatosis-from-ovarian-cancer-correlation-with-clinical-pathological-factors-and-response-to-chemotherapy
#10
Silvia Carloni, Giulia Gallerani, Anna Tesei, Emanuela Scarpi, Giorgio Maria Verdecchia, Salvatore Virzì, Francesco Fabbri, Chiara Arienti
OBJECTIVE: We investigated the correlation between ploidy or S-phase fraction (SPF) and the clinical pathological characteristics of patients with peritoneal carcinomatosis from ovarian cancer. We also assessed their relation with the in vivo and in vitro response to several chemotherapeutic agents. PATIENTS AND METHODS: Fifty-three patients with peritoneal carcinomatosis from ovarian cancer were enrolled. Frozen tumor tissue was dissociated by a detergent-trypsin method, and the resulting cell suspension was stained with RNase A and propidium iodide...
2017: OncoTargets and Therapy
https://www.readbyqxmd.com/read/29031318/symptom-clustering-and-quality-of-life-in-patients-with-ovarian-cancer-undergoing-chemotherapy
#11
Ju-Hee Nho, Sung Reul Kim, Joo-Hyun Nam
PURPOSE: The symptom clusters in patients with ovarian cancer undergoing chemotherapy have not been well evaluated. We investigated the symptom clusters and effects of symptom clusters on the quality of life of patients with ovarian cancer. METHOD: We recruited 210 ovarian cancer patients being treated with chemotherapy and used a descriptive cross-sectional study design to collect information on their symptoms. To determine inter-relationships among symptoms, a principal component analysis with varimax rotation was performed based on the patient's symptoms (fatigue, pain, sleep disturbance, chemotherapy-induced peripheral neuropathy, anxiety, depression, and sexual dysfunction)...
October 2017: European Journal of Oncology Nursing: the Official Journal of European Oncology Nursing Society
https://www.readbyqxmd.com/read/29027536/kras-mutation-of-extraovarian-implants-of-serous-borderline-tumor-prognostic-indicator-for-adverse-clinical-outcome
#12
Tao Zuo, Serena Wong, Natalia Buza, Pei Hui
In contrast to non-invasive extraovarian implants, invasive implants of ovarian serous borderline tumor/atypical proliferative serous tumor are associated with adverse outcome and have been reclassified as low-grade serous carcinoma. Mutations of KRAS and/or BRAF have been reported in up to 50% of serous borderline tumor/atypical proliferative serous tumor. We investigated KRAS and BRAF mutation frequencies in the two types of implants of serous borderline tumor/atypical proliferative serous tumor in correlation with clinical outcome...
October 13, 2017: Modern Pathology: An Official Journal of the United States and Canadian Academy of Pathology, Inc
https://www.readbyqxmd.com/read/29027398/nutritional-status-cachexia-and-anorexia-in-women-with-peritoneal-metastasis-and-intraperitoneal-chemotherapy-a-longitudinal-analysis
#13
Ziad Hilal, Günther A Rezniczek, Robert Klenke, Askin Dogan, Clemens B Tempfer
OBJECTIVE: To describe the nutritional status of women with peritoneal metastasis (PM) from recurrent ovarian, fallopian, or peritoneal cancer and to assess longitudinal variations of the cachexia-anorexia syndrome (CAS) during palliative pressurized intraperitoneal aerosol chemotherapy (PIPAC). METHODS: Nutritional assessment included body mass index (BMI), bioelectrical impedance analysis (BIA), and blood chemistry. CAS presence/absence was recorded before and during repeated cycles (1-11) of PIPAC...
November 2017: Journal of Gynecologic Oncology
https://www.readbyqxmd.com/read/29027395/prognostic-value-of-programmed-death-ligand-1-pd-l1-expression-in-ovarian-clear-cell-carcinoma
#14
Jun Zhu, Hao Wen, Rui Bi, Yong Wu, Xiaohua Wu
OBJECTIVE: Programmed death-ligand 1 (PD-L1) was expressed in various tumors and antibodies targeting its receptor programmed cell death-1 (PD-1) are emerging cancer therapeutics. This study was designed to evaluate the expression of PD-L1 and its correlation with clinicopathologic features and clinical outcomes in ovarian clear cell carcinoma (OCCC). METHODS: The PD-L1 expression was measured by tissue-microarray-based immunohistochemistry from 122 eligible patients diagnosed with OCCC...
November 2017: Journal of Gynecologic Oncology
https://www.readbyqxmd.com/read/29022007/is-uterine-preservation-combined-with-bilateral-salpingo-oophorectomy-to-promote-subsequent-fertility-safe-in-infiltrative-mucinous-ovarian-cancer
#15
Sebastien Gouy, Marine Saidani, Amandine Maulard, Matthieu Faron, Slim Bach-Hamba, Enrica Bentivegna, Alexandra Leary, Patricia Pautier, Mojgan Devouassoux-Shisheboran, Catherine Genestie, Philippe Morice
According to the latest World Health Organization classification (2014), mucinous ovarian cancers should be classified histologically as being either expansile or infiltrative. Compared to other epithelial cancers, both of these mucinous patterns are diagnosed, in the main, at an early stage, although they can affect relatively young patients. The infiltrative subtype is characterized by a morphologically and clinically more aggressive disease versus the expansile form. Consequently, even in young patients who would prefer fertility sparing management, the removal of both ovaries (even for a unilateral tumor) remains a common recommendation...
November 2017: Gynecologic Oncology Reports
https://www.readbyqxmd.com/read/29020823/platinum-or-nonplatinum-in-recurrent-ovarian-cancer-that-is-the-question
#16
Andrés Poveda, Christian Marth
Although platinum-based chemotherapy continues to be the first-line option for advanced ovarian cancer and for platinum recurrences beyond 6 months, platinum rechallenge is not the best approach for some patients, such as those with residual toxicities, platinum-related hypersensitivity reactions or limited platinum-sensitivity (i.e., a platinum treatment-free interval [TFIp] of 6-12 months). Results of the MITO-8 study called into question the role of single-agent nonplatinum-based regimens in this specific subset of ovarian cancer patients...
October 11, 2017: Future Oncology
https://www.readbyqxmd.com/read/29020821/when-nonplatinum-is-the-answer-the-role-of-trabectedin-plus-pegylated-liposomal-doxorubicin-in-recurrent-ovarian-cancer
#17
Nicoletta Colombo
Trabectedin + pegylated liposomal doxorubicin (PLD) offers a well tolerated and effective nonplatinum, nontaxane alternative for treatment of ovarian cancer patients with a treatment-free interval after platinum beyond 6 months, especially for those relapsing between 6 and 12 months and those who are not candidates to receive platinum-based therapy. Using the nonplatinum trabectedin + PLD combination gives patients time to recover from platinum-related toxicities and may restore platinum sensitivity in tumor cells...
October 11, 2017: Future Oncology
https://www.readbyqxmd.com/read/29020819/update-on-relapsed-ovarian-cancer-treatment-from-new-consensus-to-daily-clinical-practice
#18
Antonio González-Martín
The outcome of the 5th Ovarian Cancer Consensus Conference (OCCC) held in November 2015 in Tokyo, Japan, was the development of new and revised consensus statements to guide clinical investigations in ovarian cancer. The OCCC statements may also have direct application to daily clinical practice. This review examines the consensus statements for recurrent ovarian cancer and their impact on treatment paradigms. Importantly, patients are no longer to be categorized by the platinum-free interval (with its arbitrary 6-month cut-off points) but according to the question: 'is platinum still an option for the patient?' Another important change since the 4th OCCC in 2010 is the inclusion of BRCA mutation status when defining patient subgroups for entry into clinical trials...
October 11, 2017: Future Oncology
https://www.readbyqxmd.com/read/29017913/the-use-of-natural-compounds-for-the-targeting-and-chemoprevention-of-ovarian-cancer
#19
Francesca Pistollato, Ruben Calderón Iglesias, Roberto Ruiz, Silvia Aparicio, Jorge Crespo, Luis Dzul Lopez, Francesca Giampieri, Maurizio Battino
Among gynaecological cancers, ovarian cancer represents the leading cause of death in women. Current treatment for ovarian cancer entails surgery followed by combined chemotherapy with platinum and taxane, which are associated, particularly cisplatin, with severe side effects. While this treatment approach appears to be initially effective in a high number of patients, nearly 70% of them suffer a relapse within a few months after initial treatment. Therefore, more effective and better-tolerated treatment options are clearly needed...
October 7, 2017: Cancer Letters
https://www.readbyqxmd.com/read/29016487/ovarian-vein-thrombosis-incidence-of-recurrent-venous-thromboembolism-and-survival
#20
Charles J Lenz, Waldemar E Wysokinski, Stanislav Henkin, Kevin P Cohoon, Ana Casanegra, Benjamin S Simmons, Rayya A Saadiq, Paul R Daniels, Ewa M Wysokinska, Haraldur Bjarnason, Robert D McBane
OBJECTIVE: To identify the risk of venous thromboembolism recurrence, major bleeding, and mortality in patients with ovarian vein thrombosis so as to better define optimal treatment strategies. METHODS: Patients with ovarian vein thrombosis (1990-2015) and age- and gender-matched patients with contemporary leg deep vein thrombosis (DVT) were assessed for differences in etiology, venous thromboembolism recurrence, and survival in a case-control study. RESULTS: Over the timeframe of this study, only 219 ovarian vein thrombosis cases were identified compared with 13,417 leg DVTs...
October 6, 2017: Obstetrics and Gynecology
keyword
keyword
103066
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"